Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / IBRX - ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities Risks And Potential Gains

IBRX - ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities Risks And Potential Gains

ImmunityBio Inc.

2024-04-23 17:11:27 ET

Summary

  • San Diego-based biotech company ImmunityBio has received its first US drug approval for its lead drug candidate Anktiva, an immunotherapy for bladder cancer.
  • Anktiva received Breakthrough Therapy Designation and approval from the FDA based on its safety and efficacy outcomes, which appear to have "best-in-class" potential.
  • ImmunityBio's founder, Dr. Patrick Soon-Shiong, owns the majority of the company and plans to launch five new drugs between 2021 and 2025. The entrepreneur has been remarkably successful in pharma.

Investment Overview

ImmunityBio ( IBRX ), the San Diego-based biotech led by well-known biotech entrepreneur Dr. Patrick Soon-Shiong, was celebrating today as the company scored its first US drug approval, for its lead drug candidate Anktiva....

For further details see:

ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains
Stock Information
Company Name: ImmunityBio Inc.
Stock Symbol: IBRX
Market: NASDAQ
Website: immunitybio.com
Menu
IBRX IBRX Quote IBRX Short IBRX News IBRX Articles IBRX Message Board
Get IBRX Alerts

News, Short Squeeze, Breakout and More Instantly...